Use of CGMP-phosphodiesterase inhibitors to treat impotence

摘要

The use of compounds of formula (I) (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4- methylenedioxyphenyl)-pyrazino[2',1': 6,1]pyrido[3,4-b]indole- 1,4-dione, (3S,6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6- (3,4-methylenedioxyphenyl)-pyrazino[2',1': 6,1]pyrido[3,4- b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in the treatment of impotence.